EN DE
Watch Bioretec Oy for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bioretec Oy (BRETEC) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Bioretec Oy stock €0.02, price €0.02, that is 6.0% below the price, quality 25 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FI

BO Bioretec Oy logo Thin data Nov 17, 2026

Bioretec Oy

BRETEC · HE

The stock is already about fairly priced and weak company.

Get notified free when this changes
Low debt 
Fair value €0.0229 · Fairly valued 
Expensive Growth (revenue 5y +18.6 %/yr in EUR) 
Quality 25/100 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 41/100 · thin data
Thin data 
Estimate
Watch Bioretec Oy for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.26 €0.0116 Fair Value €0.0229 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range €0.0116 – €3.26 · fair‑value band €0.0218 – €0.0241 · the €0.0244 price screens above the €0.0229 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Bioretec Oy in your weekly email

Every Wednesday you see whether Bioretec Oy is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide.

Show moreShow less

The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery.

It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants.

The company was formerly known as BCI Bioabsorbable Concepts Oy. The company was incorporated in 1998 and is headquartered in Tampere, Finland.

Stock analysis

Bioretec Oy (BRETEC) currently trades at €0.0244, while our estimate is €0.0229, so the stock looks roughly fairly valued today (gap 6.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.0218 (bear) to €0.0241 (bull), the price of €0.0244 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Bioretec Oy reported revenue of €3.5M in FY2025 versus €2.0M in FY2021, a compound +15.2%/yr. Reported net income was −€9.5M in FY2025.

Key figures

Market cap €32.7M Micro · EPS (TTM) €−0.0200 · Return on equity −4,861% · Return on assets (EBIT) −47.2% (5-year average) · Free cash flow −€10.3M · Net debt €506K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 97% below its 52-week high and 110% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −6%, BRETEC screens cheaper than that median.

Fair Value

Bear €0.0218 Fair Value €0.0229 Bull €0.0241
Price €0.0244 · Downside -6.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 1
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 6
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−22.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−128.4% (2020) → −246.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BRETEC, get fair value alerts →

Compare Bioretec Oy with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −6.1% · Above median
Profitability
Return on assets −81.2% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.69× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bioretec Oy: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bioretec Oy Fair Value". https://www.fairvalue-calculator.com/stock/BRETEC

Frequently asked questions

Is Bioretec Oy (BRETEC) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is €0.0229 versus a price of €0.0244, about 6% lower (fairly valued).
What is the fair value of BRETEC?
Our estimate for Bioretec Oy is €0.0229 (as of Nov 17, 2026), built from audited fundamentals. The current price: €0.0244.
What is the quality score of BRETEC?
Bioretec Oy has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bioretec Oy (BRETEC)?
Our calculated price target is the estimate of €0.0229 (as of Nov 17, 2026). Cautious scenario €0.0218, optimistic scenario €0.0241. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Bioretec Oy stock forecast for 2026?
Our estimate puts fair value at €0.0229, about 6% lower versus a price of €0.0244 (fairly valued). Cautious scenario €0.0218, optimistic scenario €0.0241. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Bioretec Oy (BRETEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bioretec Oy it is €0.0229 per share (as of Nov 17, 2026), against a price of €0.0244.
Is Bioretec Oy stock overvalued or undervalued in 2026?
As of Nov 17, 2026, BRETEC trades above its calculated fair value: price €0.0244, fair value €0.0229, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRETEC?
No. The price is what the market pays today (€0.0244); the fair value is what the company's own numbers justify (€0.0229). For Bioretec Oy the two are €0.0015 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bioretec Oy worth?
The market values Bioretec Oy at about €32.7M (market capitalisation, as of Nov 17, 2026). Per share that is €0.0244; our models calculate a fair value of €0.0229 per share.
What do the bullish and bearish scenarios say about BRETEC?
Our models span a range for Bioretec Oy: cautious scenario €0.0218, base €0.0229, optimistic €0.0241 per share (as of Nov 17, 2026, price €0.0244). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bioretec Oy (BRETEC)?
Balance-sheet figures for Bioretec Oy (as of Nov 17, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is BRETEC from its 52-week high?
Bioretec Oy trades at €0.0244, about 97% below its 52-week high of €0.8300 and 110% above the low of €0.0116 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of €0.0229 is for.
Which stocks are comparable to Bioretec Oy?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bioretec Oy stock attractive at the current price?
The data as of Nov 17, 2026: price €0.0244, calculated fair value €0.0229 (−6%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Bioretec Oy itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bioretec Oy (BRETEC)?
The closing price on Nov 16, 2026 was €0.0244. Our estimate is €0.0229, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bioretec Oy right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (€0.0218 to €0.0241), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Bioretec Oy

How large is the market capitalisation of Bioretec Oy (BRETEC)?
The market capitalisation of Bioretec Oy is €32.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Bioretec Oy (BRETEC)?
Earnings per share at Bioretec Oy are €−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bioretec Oy (BRETEC)?
The return on equity (ROE) of Bioretec Oy is −4,861% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bioretec Oy (BRETEC)?
On an EBIT basis the return on assets of Bioretec Oy is −47.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Bioretec Oy (BRETEC) generate?
The free cash flow of Bioretec Oy is −€10.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bioretec Oy (BRETEC) carry?
The net debt of Bioretec Oy is €506K (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bioretec Oy in the live analysis

One click puts Bioretec Oy on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.